Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION A 505(b)(2) program relying on literature plus a bridging study cannot treat a CMO 483 that maps to the NDA CMC module as incidental context on complete-response-letter deficiency list. RWE evidence-strategy director must close to drop a secondary from that extract under Pharma & Life Sciences / FDA Response and Labeling.

DECISION RWE evidence-strategy director in a 505(b)(2) program relying on literature plus a bridging study must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using complete-response-letter deficiency list after a CMO 483 that maps to the NDA CMC module.

HYPOTHESES TO TEST 1. Authorize Proceed under protocol now; complete-response-letter deficiency list already has the discriminator after a CMO 483 that maps to the NDA CMC module. 2. Keep Pause the pathway in force until complete-response-letter deficiency list is completed after a CMO 483 that maps to the NDA CMC module for RWE evidence-strategy director. 3. Treat complete-response-letter deficiency list as Escalate safety review because both readings appear after a CMO 483 that maps to the NDA CMC module. 4. Refuse a Pharma & Life Sciences close: RWE evidence-strategy director does not have the decision to drop a secondary turns on in complete-response-letter deficiency list.

ANALYSIS REQUIRED 1. Separate an isolated adverse event from a systemic quality issue. 2. Test a protocol deviation versus a safety signal versus a filing gap on to drop a secondary. 3. Check whether complete-response-letter deficiency list supports the labeled claim RWE evidence-strategy director would keep. 4. For this Pharma & Life Sciences FDA Response and Labeling file, read complete-response-letter deficiency list against a CMO 483 that maps to the NDA CMC module and write the one fact that would move to drop a secondary for RWE evidence-strategy director.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / FDA Response and Labeling packet (complete-response-letter deficiency list after a CMO 483 that maps to the NDA CMC module). Lead with the Pharma & Life Sciences option complete-response-letter deficiency list can support after a CMO 483 that maps to the NDA CMC module, then the two facts that force it, then the Monday action for RWE evidence-strategy director in a 505(b)(2) program relying on literature plus a bridging study.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to drop a secondary, then the evidence in complete-response-letter deficiency list, then the action for RWE evidence-strategy director - Hypothesis scorecard against complete-response-letter deficiency list: supported / rejected / untestable - Owner and next date for RWE evidence-strategy director in a 505(b)(2) program relying on literature plus a bridging study - What changes to drop a secondary if a CMO 483 that maps to the NDA CMC module is later withdrawn